Mark Lappe
Chief Executive Officer chez INHIBRX, INC.
Fortune : 106 M $ au 31/03/2024
Profil
Mark P.
Lappe is the founder of Lappe & Associates, Inc. (founded in 1990), Efficacy Capital LLC (founded in 2004), Inhibrx LP (founded in 2010), and Inhibrx, Inc. (founded in 2010).
He is also the founder of Efficacy Biotech Fund LP.
Mr. Lappe's current job is Chairman, President & Chief Executive Officer at Inhibrx Biosciences, Inc. and Managing Partner at Efficacy Capital Ltd.
His former jobs include Chairman at Repros Therapeutics, Inc. (2008-2009) and Non-Executive Director at Osmetech Ltd.
(2009-2009).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INHIBRX INC
6,43% | 21/02/2024 | 3 045 654 ( 6,43% ) | 106 M $ | 31/03/2024 |
Postes actifs de Mark Lappe
| Sociétés | Poste | Début |
|---|---|---|
| INHIBRX, INC. | Chief Executive Officer | 01/04/2010 |
| Efficacy Capital Ltd. | Corporate Officer/Principal | 10/06/2009 |
Anciens postes connus de Mark Lappe
| Sociétés | Poste | Fin |
|---|---|---|
| REPROS THERAPEUTICS INC | Chairman | 12/11/2009 |
Osmetech Ltd.
 Osmetech Ltd. Medical/Nursing ServicesHealth Services Osmetech Ltd. designs, develops, manufactures and sells molecular diagnostics instruments and consumables enabling deoxyribonucleic acid, ribonucleic acid and protein testing. Its operates in Atlanta, Boston and Pasadena in the US, serving the growth, near patient testing market targeting small to medium sized hospitals. Osmetech was founded in 1993 and is headquartered in London, the United Kingdom. | Director/Board Member | 28/08/2009 |
| Efficacy Biotech Fund LP | Founder | - |
Inhibrx LP
 Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Chief Executive Officer | - |
Efficacy Capital LLC
 Efficacy Capital LLC Investment ManagersFinance Founded in 2004 by Mark Paul Lappe and Jon Faiz Kayyem, Efficacy Capital LLC is a hedge fund manager located in La Jolla, California. The firm provides investment management services primarily to high net-worth individuals. They also manage pooled investment vehicles, including hedge funds and mutual funds | Founder | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INHIBRX, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Repros Therapeutics, Inc.
 Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
| Efficacy Capital Ltd. | |
| Efficacy Biotech Fund LP | |
Osmetech Ltd.
Osmetech Ltd. Medical/Nursing ServicesHealth Services Osmetech Ltd. designs, develops, manufactures and sells molecular diagnostics instruments and consumables enabling deoxyribonucleic acid, ribonucleic acid and protein testing. Its operates in Atlanta, Boston and Pasadena in the US, serving the growth, near patient testing market targeting small to medium sized hospitals. Osmetech was founded in 1993 and is headquartered in London, the United Kingdom. | Health Services |
| Lappe & Associates, Inc. | |
Efficacy Capital LLC
Efficacy Capital LLC Investment ManagersFinance Founded in 2004 by Mark Paul Lappe and Jon Faiz Kayyem, Efficacy Capital LLC is a hedge fund manager located in La Jolla, California. The firm provides investment management services primarily to high net-worth individuals. They also manage pooled investment vehicles, including hedge funds and mutual funds | Finance |
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
